Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brexpiprazole in Adolescents With Schizophrenia
NCT02411695Phase 1Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Mar 2015
- Primary completion
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of brexpiprazole in schizophrenia and bipolar disorder (BD) (5 cohorts), sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoints: Reported Adverse Events, Change from Baseline in Vital Signs at Day 17 and 12 more. Started Mar 2015; status: completed.
02
Drugs
brexpiprazole
03
Conditions
schizophreniabipolar disorder (BD)
Beyond the preview
Go deeper on NCT02411695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02411695.